Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide

Next Previous
Trial Profile

A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 3726 (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca; MedImmune

    • Most Recent Events

    • 01 Apr 2021 The protocol was amended to alter the pattern of dose escalation from the ~100% proportional increase used initially to incorporate selected intermediate dose cohorts (0.2 and 0.25 mg/kg)as per result published in Clinical Cancer Research
    • 01 Apr 2021 Results (n= 33 as of data cutoff date-17 January, 2020), "evaluating safety and preliminary efficacy data from the dose-escalation portion of MEDI3726 monotherapy in patients with metastatic castration-resistant prostate cancer published in the Clinical Cancer Research
    • 15 Feb 2020 Results (n=33, as of Sept 27 2019) presented at the 2020 Genitourinary Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top